Capricor Therapeutics (CAPR) FCF Margin (2011 - 2024)
Capricor Therapeutics (CAPR) recorded quarterly FCF Margin of 137.33% in Q4 2024, up 73.34% quarter-over-quarter from 515.18% in Q3 2024, and down 3679.0% on a YoY basis from 3.84% in Q1 2024.
Capricor Therapeutics (CAPR) FCF Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' FCF Margin history runs 14 years deep, the most recent figure standing at 137.33% for Q4 2024.
- In Q4 2024, FCF Margin fell 3679.0% year-over-year to 137.33%; the TTM figure through Sep 2025 stood at 563.94% (down 42966.0% YoY), while the FY2024 annual figure was 184.83%, down 7796.0% from the prior year.
- FCF Margin was 137.33% for Q4 2024 at Capricor Therapeutics, up from 515.18% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 129.32% in Q1 2023 to a low of 18558.95% in Q3 2020.
- Historically, FCF Margin has averaged 2735.15% across 5 years, with a median of 453.73% in 2024.
- The sharpest annual moves came in 2020 and 2021: FCF Margin plunged 1739659 bps in 2020, then soared 188979 bps in 2021.
- A 5-year view of FCF Margin shows it stood at 7142.52% in 2020, then soared by 67 bps to 2370.08% in 2021, then surged by 67 bps to 791.34% in 2022, then jumped by 87 bps to 100.53% in 2023, then plunged by 37 bps to 137.33% in 2024.
- The last three FCF Margin figures came in at 137.33% (Q4 2024), 515.18% (Q3 2024), and 310.94% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -137.33% |
| Sep 30, 2024 | -515.18% |
| Jun 30, 2024 | -310.94% |
| Mar 31, 2024 | -18.77% |
| Dec 31, 2023 | -100.53% |
| Sep 30, 2023 | -146.53% |
| Jun 30, 2023 | -243.87% |
| Mar 31, 2023 | 129.32% |
| Dec 31, 2022 | -791.34% |
| Sep 30, 2022 | -392.27% |
| Jun 30, 2021 | -2,370.08% |
| Mar 31, 2021 | -8,247.46% |
| Dec 31, 2020 | -7,142.52% |
| Sep 30, 2020 | -18,558.95% |
| Jun 30, 2020 | -4,259.87% |
| Mar 31, 2020 | -656.01% |
| Dec 31, 2019 | -803.71% |
| Sep 30, 2019 | -1,162.36% |
| Jun 30, 2019 | -433.14% |
| Mar 31, 2019 | -697.47% |